Good
Mostly Aligned
Patient Risk:
Low
Summary
The response is largely consistent with the provided OZEMPIC (semaglutide) label excerpts for thyroid C-cell tumors/MTC risk, but it includes multiple brand/indication statements that are not supported by the supplied label text.
Category Scores
Accurate Statements
Thyroid C-cell tumors / MTC risk is supported by the label.
Supported by Section 5.1 (rodent thyroid C-cell tumors; unknown human relevance), Section 4 (contraindication for personal/family history of MTC or MEN 2), Section 17 (patient counseling on symptoms), and Section 13.1 (carcinogenicity findings and human relevance unknown).
OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2.
Section 4 Contraindications.
It is unknown whether OZEMPIC causes thyroid C-cell tumors (including MTC) in humans.
Section 5.1 Risk of Thyroid C-Cell Tumors.
Patients should be counseled regarding potential risk for MTC and symptoms (e.g., lump in the neck, dysphagia, dyspnea, persistent hoarseness).
Section 5.1 (counseling and symptoms) and Section 17 (Risk of Thyroid C-cell Tumors).
Unsupported Statements
Semaglutide is sold under different brand names depending on the form and country.
Not supported by the provided OZEMPIC label excerpts.
In the U.S., Ozempic is semaglutide injection for type 2 diabetes.
Type 2 diabetes indication statements are not supported by the provided excerpts (the supplied label text focuses on MTC risk).
In the U.S., Wegovy is semaglutide for chronic weight management.
Not supported by the provided OZEMPIC label excerpts.
In the U.S., Rybelsus is oral semaglutide for type 2 diabetes.
Not supported by the provided OZEMPIC label excerpts.
Wegovy is used for weight management.
Not supported by the provided OZEMPIC label excerpts.
Ozempic is used for type 2 diabetes.
Not supported by the provided OZEMPIC label excerpts.
Rybelsus (oral) is used for type 2 diabetes.
Not supported by the provided OZEMPIC label excerpts.
Semaglutide’s brand name can vary by country and by dosing form (injectable vs oral).
Not supported by the provided OZEMPIC label excerpts.
Contradictions
Low
AI Statement
The boxed warning is specifically tied to thyroid C-cell tumors/MTC risk.
Label Reference
The provided label excerpts show the risk described in Section 5.1 and relate contraindications and counseling, but the response’s boxed-warning-specific determination is inconsistent with the provided assessment text included in the prompt.
Important Omissions
No label-based dosing, administration, or monitoring details beyond the provided counseling/monitoring caveat were evaluated or stated for the non-MTC claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The portion related to thyroid C-cell tumors/MTC risk aligns with the provided label excerpts, including contraindications and patient counseling. However, multiple unrelated brand/indication statements are not supported by the provided label text, reducing label-alignment accuracy.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several claims about other semaglutide brand names and indications (Ozempic/Wegovy/Rybelsus indications and country/form relationships) are not supported by the supplied OZEMPIC label excerpts.
Suggested Improvement
Limit claims to information explicitly present in the provided OZEMPIC label excerpts (MTC risk, contraindication for MTC/MEN 2, and patient counseling/monitoring caveats). Exclude or qualify brand/indication statements not contained in the provided label text.